Arecor signs a new formulation evaluation agreement with an existing partner, a major global pharmaceutical company


09-07-2019

Arecor Ltd , the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company.

Under this new agreement, Arecor will use its proprietary formulation technology platform Arestat™ to develop a differentiated, thermostable liquid formulation of one of the global pharmaceutical company’s key proprietary products.  The new formulation will be stored at room temperature to improve the ease of use of the product by healthcare providers and patients, whilst also simplifying the supply chain.  The pharmaceutical company will fund the development work and has the option to acquire the rights to the new proprietary formulation and associated Intellectual Property under a technology licensing model.

Sarah Howell, Chief Executive Officer at Arecor, said:  "This additional collaboration with an existing partner further demonstrates the value of our innovative, Arestat™ technology platform.  We are focused on leveraging ArestatTM to deliver superior reformulations of key products that can improve patient care as well as add commercial value to our partners.  This new agreement validates both the commercial value of Arestat™, and the strength and breadth of our scientific reformulation and development expertise.”

 

 

Arecor Limited, located on the Cambridge Science Park, was established to provide formulation solutions to pharmaceutical and biotech companies developing drugs, vaccines, medical devices and diagnostics.

Arecor Ltd